1Iguchi T, Nomura K, Tomioka R, et al. Relationship between clinical activity and lymphocyte subsets in patients with Guillain-Barre syndrome[J], Jan Rinsho Shinkeigaku, 2001,41 (1):11 17.
1[7]Hehmke B, Salzsieder E, Matic GB, et al. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune dis eases. Ther Apher, 2000,4 (4) : 296 ～ 302.
2[8]Schneider KM. Plasmapheresis and immunoadsorption: different techniques and their current role in medical therapy. kidney Int Suppl, 1998, 53,61～65.
3[9]Hirayama K, Koyama A. Adverse effects of plasma exchange.Nippon Rinsho,2004,62 Suppl 5:319～322.
4[1]Kaplan AA. The use of apheresis in immune renal disorders.Therap Apher Dial, 2003,27 (2): 165 ～ 172.
5[2]Braun N,Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther Apher, 1999,3 (3) : 240 ～ 245.
6[3]Matic G, Bosch T, Ramlow W. Background and indications for protein A- based extracorporeal immunoadsorption. Ther Apher,2001,5(5) :394～403.
7[4]Ullrich H, Kuehnl P. New trends in specific immunoadsorption.Transfus Apheresis Sci,2004,30(3):223～231.
8[5]Madore F. Plasmapheresis. Technical aspects and indications. Crit Care Clin,2002,18(2) :375～392.
9[6]Braun N, Bosch T. Immunoadsorption, current status and future developments. Expert Opin Investig Drugs, 2000,9 ( 9 ): 2017 ～2038.
10Nakaji S.Current topics on immunoadsorption therapy.Ther Apher,2001,5(4):301-305.
